Average cost per year*
Average cost per beneficiary*
Beovu is a prescription medication used for the treatment of certain eye conditions, including age-related macular degeneration (AMD). It contains brolucizumab and helps slow down disease progression. While Beovu can be effective in managing eye conditions, it does not offer a cure. To achieve optimal outcomes and minimize potential side effects, receive Beovu as directed by your ophthalmologist. Regular eye examinations and follow-up are crucial during treatment. This summary provides an overview and may not encompass all available information about the product. It does not guarantee the product's safety, effectiveness, or suitability for your individual situation. Consult your healthcare professional for comprehensive information and individualized recommendations.
*Origin of the terms and chart data used within this page: https://data.cms.gov/
Yes, Beovu is covered by Medicare.
In 2021, the average cost per dose of Beovu was $39,059.64.
The average dose of Beovu received per year is 6 units
71 Medicare beneficiaries received Beovu in 2021, which was a -0.11% from 2020
There were 234 claims made by Medicare beneficiaries, which is a -0.15% from 2020
The average spending amount per claim in 2021 was $2,336.90
The average Medicare spending per beneficiary amount for Beovu was $7,701.90
Novartis received $546,834.95
The total amount spent on Beovu by Medicare is $546,834.95
Short Term Medical Insurance
Limited Fixed Indemnity Plans